From helping with the discovery of Cisplatin in 1977 until the present day, Johnson Matthey Fine Chemicals continues to be the industry leader in platinum and other APIs containing solubilised metal. We bring unparalleled development and manufacturing expertise for the most advanced prostaglandins, strengthened by the acquisition of Cascade Biochem in 2003. Including ultra-pure prostaglandins with significant scale-up, we can meet your most complex specifications and global prostaglandin API needs.
We have developed a number of difficult-to-synthesise APIs for both the innovator and generic markets, for over 40 years. Our APIs comply with the highest regulatory requirements specified by leading health authorities such as the FDA, PMDA, TGA, ANVISA and EU authorities.